Merck & Co., Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Feb 26, 2024 and accepted by EDGAR at Feb 26, 2024, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | $60.12bn | us-gaap:Revenues |
| Cost of revenue | 12 months2023-01-01 to 2023-12-31 | $16.13bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2023-01-01 to 2023-12-31 | $30.53bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2023-01-01 to 2023-12-31 | $10.50bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $1.15bn | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $1.51bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | $365.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | $0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 2,547,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $3.86bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2023-01-01 to 2023-12-31 | $7.45bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months2023-01-01 to 2023-12-31 | $1.35bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-12-31 | $6.84bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $32.17bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $106.67bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $25.69bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-12-31 | $33.68bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-12-31 | $1.30bn | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-12-31 | $37.58bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-006850. Last ingested by Listed: Oct 29, 2026, 06:44 ET. Listed shows no prices and gives no investment advice.